MonoTx

MonoTx is a pre-clinical stage biotechnology company focused on developing next-generation immunotherapies by targeting Toll-like receptors (TLRs). The company's primary focus is on the development of potent and selective TLR7/8 agonists designed to stimulate the innate immune system to treat solid tumors and infectious diseases. By leveraging a proprietary platform, MonoTx aims to create therapies that can overcome the limitations of current immune-oncology treatments, particularly in 'cold' tumors that do not typically respond to checkpoint inhibitors. The company is currently advancing its lead candidates through IND-enabling studies.